MP 4

Drug Profile

MP 4

Alternative Names: Apogen - multiple sclerosis; Apogen MS

Latest Information Update: 17 Nov 2003

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Alexion Pharmaceuticals; National Institutes of Health (USA)
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Multiple sclerosis

Most Recent Events

  • 31 Jan 2003 Suspended - Phase-I for Multiple sclerosis in USA (unspecified route)
  • 09 Dec 2002 Phase-I clinical trials in Multiple sclerosis in USA (unspecified route)
  • 13 Jun 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top